TherapeuticsMD Inc. [NASDAQ: TXMD] plunged by -$0.05 during the normal trading session on Tuesday and reaching a high of $1.285 during the day while it closed the day at $1.23. The company report on April 9, 2021 that TherapeuticsMD and Theramex Announce the Approval of BIJUVE® Capsules Indicated for Hormone Replacement Therapy in the United Kingdom and Under the Trade Name BIJUVA® in Belgium.
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, and Theramex, a dedicated women’s health company, announced that BIJUVE® has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for use in the United Kingdom and, from the Federal Agency for Medicines and Health Products (FAMHP) for use in Belgium under BIJUVA®.
A “decentralized procedure” (DCP) for the regulatory approval of BIJUVA® in several European countries was completed in February. Following this each country undertakes a national process which includes approvals for labeling and other country specific requirements. Theramex expects approvals from other major EU countries shortly.
TherapeuticsMD Inc. stock has also loss -9.56% of its value over the past 7 days. However, TXMD stock has declined by -13.38% in the 3 months of the year. Over the past six months meanwhile, it has lost -25.45% and gained 1.65% year-on date.
The market cap for TXMD stock reached $476.99 million, with 286.69 million shares outstanding and 266.15 million shares in the current float. Compared to the average trading volume of 15.56M shares, TXMD reached a trading volume of 11091409 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about TherapeuticsMD Inc. [TXMD]:
Jefferies have made an estimate for TherapeuticsMD Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on August 07, 2020. The new note on the price target was released on May 19, 2020, representing the official price target for TherapeuticsMD Inc. stock.
The Average True Range (ATR) for TherapeuticsMD Inc. is set at 0.11, with the Price to Sales ratio for TXMD stock in the period of the last 12 months amounting to 7.35.
TXMD stock trade performance evaluation
TherapeuticsMD Inc. [TXMD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -9.56. With this latest performance, TXMD shares dropped by -22.64% in over the last four-week period, additionally sinking by -25.45% over the last 6 months – not to mention a rise of 34.99% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TXMD stock in for the last two-week period is set at 34.07, with the RSI for the last a single of trading hit 26.64, and the three-weeks RSI is set at 38.63 for TherapeuticsMD Inc. [TXMD]. The present Moving Average for the last 50 days of trading for this stock 1.5757, while it was recorded at 1.2940 for the last single week of trading, and 1.4957 for the last 200 days.
TherapeuticsMD Inc. [TXMD]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and TherapeuticsMD Inc. [TXMD] shares currently have an operating margin of -239.76 and a Gross Margin at +73.77. TherapeuticsMD Inc.’s Net Margin is presently recorded at -282.90.
Return on Total Capital for TXMD is now -91.74, given the latest momentum, and Return on Invested Capital for the company is -109.45. Additionally, TXMD Total Debt to Total Capital is recorded at 199.50, with Total Debt to Total Assets ending up at 136.90.
Reflecting on the efficiency of the workforce at the company, TherapeuticsMD Inc. [TXMD] managed to generate an average of -$458,810 per employee. Receivables Turnover for the company is 2.29 with a Total Asset Turnover recorded at a value of 0.29.TherapeuticsMD Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.00 and a Current Ratio set at 2.20.
Earnings per share (EPS) analysis for TherapeuticsMD Inc. [TXMD] stock
With the latest financial reports released by the company, TherapeuticsMD Inc. posted -0.21/share EPS, while the average EPS was predicted by analysts to be reported at -0.19/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -10.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TXMD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for TherapeuticsMD Inc. go to 17.60%.
TherapeuticsMD Inc. [TXMD]: Insider Ownership positions
There are presently around $198 million, or 42.70% of TXMD stock, in the hands of institutional investors. The top three institutional holders of TXMD stocks are: BLACKROCK INC. with ownership of 21,419,273, which is approximately 14.593% of the company’s market cap and around 5.10% of the total institutional ownership; PRICE T ROWE ASSOCIATES INC /MD/, holding 18,869,212 shares of the stock with an approximate value of $23.21 million in TXMD stocks shares; and FMR LLC, currently with $17.36 million in TXMD stock with ownership of nearly -1.354% of the company’s market capitalization.
Positions in TherapeuticsMD Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 74 institutional holders increased their position in TherapeuticsMD Inc. [NASDAQ:TXMD] by around 31,587,469 shares. Additionally, 50 investors decreased positions by around 27,941,194 shares, while 45 investors held positions by with 101,654,947 shares. The mentioned changes placed institutional holdings at 161,183,610 shares, according to the latest SEC report filing. TXMD stock had 29 new institutional investments in for a total of 12,600,005 shares, while 11 institutional investors sold positions of 2,641,546 shares during the same period.